Gossamer Bio FY2028 EPS Forecast Lifted by HC Wainwright

Posted by Francis Steltz on Jun 3rd, 2026

Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) – Equities researchers at HC Wainwright boosted their FY2028 earnings per share (EPS) estimates for Gossamer Bio in a research note issued on Monday, June 1st. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.13) per share for the year, up from their prior estimate of ($0.16). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.52) per share. HC Wainwright also issued estimates for Gossamer Bio’s FY2029 earnings at ($0.06) EPS.

Gossamer Bio (NASDAQ:GOSS – Get Free Report) last posted its quarterly earnings data on Monday, May 18th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $16.96 million during the quarter, compared to the consensus estimate of $4.67 million.

Other equities research analysts also recently issued research reports about the company. Cantor Fitzgerald restated a “neutral” rating on shares of Gossamer Bio in a research report on Monday, March 23rd. Leerink Partners downgraded Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Wedbush restated a “neutral” rating and set a $1.00 target price (down from $6.00) on shares of Gossamer Bio in a research report on Tuesday, February 24th. Barclays downgraded Gossamer Bio from an “overweight” rating to an “underweight” rating in a research report on Tuesday, February 24th. Finally, Weiss Ratings downgraded Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 19th. Four analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $5.00.

View Our Latest Report on GOSS

Gossamer Bio Stock Up 1.1%

GOSS stock opened at $0.20 on Wednesday. The company has a market cap of $46.99 million, a P/E ratio of -0.25 and a beta of 2.00. Gossamer Bio has a twelve month low of $0.16 and a twelve month high of $3.87. The business has a fifty day moving average of $0.33 and a 200-day moving average of $1.66.

Institutional Investors Weigh In On Gossamer Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GOSS. Legal & General Group Plc bought a new stake in Gossamer Bio in the second quarter valued at about $26,000. Banco BTG Pactual S.A. bought a new stake in Gossamer Bio in the second quarter valued at about $27,000. MMA Asset Management LLC bought a new stake in Gossamer Bio in the fourth quarter valued at about $31,000. Soltis Investment Advisors LLC bought a new stake in Gossamer Bio in the fourth quarter valued at about $31,000. Finally, Beacon Pointe Advisors LLC bought a new stake in Gossamer Bio in the fourth quarter valued at about $34,000. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

(Get Free Report)

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.